BC Week In Review | May 21, 2012
Company News

Neurotune, ALS Therapy Development Institute (ALS TDI) deal

ALS TDI said it will evaluate the efficacy of Neurotune's TDI-165 in a preclinical model of amyotrophic lateral sclerosis (ALS). TDI-165 is a biologic targeted at stabilizing the neuromuscular junction. Details were not disclosed. Neurotune...
BC Week In Review | Mar 26, 2012
Company News

Neurotune sales and marketing update

Neurotune launched NTCAF ELISA to diagnose sarcopenia. The ELISA-based diagnostic for detection of 22kDa C-terminal agrin fragment (CAF) in human serum was developed in collaboration with MicroCoat Biotechnologie GmbH (Bernried, Germany) and the Eureka-Eurostars programme,...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Musculoskeletal disease Muscle atrophy Angiotensin II type 1 receptor (AGTR1) A study in mice suggests AGTR1 blockers could help treat muscle atrophy. In mouse models of age- and disuse-related muscle atrophy,...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
BC Week In Review | Apr 18, 2011
Company News

Neurotune management update

Neurotune AG , Schlieren, Switzerland   Business: Neurology, Musculoskeletal   Transitioned: Armin Mader to CEO from CFO; he replaces Executive Chairman Bruno Oesch, who will now focus on strategic and business development  ...
BC Week In Review | Nov 8, 2010
Clinical News

Dimiracetam: Phase IIa data

Top-line data from an 8-week, double-blind, placebo-controlled, South African Phase IIa trial in 116 patients showed that dimiracetam was well tolerated at doses of up to 1,600 mg twice daily. There were no significant differences...
BioCentury | Aug 23, 2010
Regulation

Run off the road

Eli Lilly and Co. may have thought FDA had provided a roadmap that would have made Cymbalta duloxetine the first non-opioid and non-NSAID to be approved for a broad label for chronic pain. But the...
BC Innovations | Dec 3, 2009
Targets & Mechanisms

Good touch, bad touch

University of California, San Francisco researchers have identified the precise spinal cord neurons that cause hypersensitivity to gentle touches, a common form of neuropathic pain associated with injury and inflammation. 1 The study also presents...
BC Innovations | Apr 2, 2009
Cover Story

New PrPetrator in AD

Yale University researchers have uncovered a surprising link between Alzheimer's disease and the prion protein that has been linked to mad cow disease and the related human condition, Creutzfeldt-Jakob disease. The team has reported that...
BC Week In Review | Jan 26, 2009
Clinical News

Dimiracetam: Phase I data

A 2-part, Swiss Phase I trial in 56 healthy volunteers showed that oral dimiracetam was well tolerated. There were no clinically relevant effects of food on pharmacokinetics. The trial consisted of a single-dose assessment of...
Items per page:
1 - 10 of 16
BC Week In Review | May 21, 2012
Company News

Neurotune, ALS Therapy Development Institute (ALS TDI) deal

ALS TDI said it will evaluate the efficacy of Neurotune's TDI-165 in a preclinical model of amyotrophic lateral sclerosis (ALS). TDI-165 is a biologic targeted at stabilizing the neuromuscular junction. Details were not disclosed. Neurotune...
BC Week In Review | Mar 26, 2012
Company News

Neurotune sales and marketing update

Neurotune launched NTCAF ELISA to diagnose sarcopenia. The ELISA-based diagnostic for detection of 22kDa C-terminal agrin fragment (CAF) in human serum was developed in collaboration with MicroCoat Biotechnologie GmbH (Bernried, Germany) and the Eureka-Eurostars programme,...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Musculoskeletal disease Muscle atrophy Angiotensin II type 1 receptor (AGTR1) A study in mice suggests AGTR1 blockers could help treat muscle atrophy. In mouse models of age- and disuse-related muscle atrophy,...
BC Innovations | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Autoimmune disease Autoimmune disease CD28; inducible T cell co-stimulator ligand (ICOSLG; B7-H2) In vitro and cell culture studies suggest inhibiting interactions between B7-H2 and CD28 could help treat autoimmune disease. An...
BC Week In Review | Apr 18, 2011
Company News

Neurotune management update

Neurotune AG , Schlieren, Switzerland   Business: Neurology, Musculoskeletal   Transitioned: Armin Mader to CEO from CFO; he replaces Executive Chairman Bruno Oesch, who will now focus on strategic and business development  ...
BC Week In Review | Nov 8, 2010
Clinical News

Dimiracetam: Phase IIa data

Top-line data from an 8-week, double-blind, placebo-controlled, South African Phase IIa trial in 116 patients showed that dimiracetam was well tolerated at doses of up to 1,600 mg twice daily. There were no significant differences...
BioCentury | Aug 23, 2010
Regulation

Run off the road

Eli Lilly and Co. may have thought FDA had provided a roadmap that would have made Cymbalta duloxetine the first non-opioid and non-NSAID to be approved for a broad label for chronic pain. But the...
BC Innovations | Dec 3, 2009
Targets & Mechanisms

Good touch, bad touch

University of California, San Francisco researchers have identified the precise spinal cord neurons that cause hypersensitivity to gentle touches, a common form of neuropathic pain associated with injury and inflammation. 1 The study also presents...
BC Innovations | Apr 2, 2009
Cover Story

New PrPetrator in AD

Yale University researchers have uncovered a surprising link between Alzheimer's disease and the prion protein that has been linked to mad cow disease and the related human condition, Creutzfeldt-Jakob disease. The team has reported that...
BC Week In Review | Jan 26, 2009
Clinical News

Dimiracetam: Phase I data

A 2-part, Swiss Phase I trial in 56 healthy volunteers showed that oral dimiracetam was well tolerated. There were no clinically relevant effects of food on pharmacokinetics. The trial consisted of a single-dose assessment of...
Items per page:
1 - 10 of 16